Compare ALBT & LYRA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | ALBT | LYRA |
|---|---|---|
| Founded | 2014 | 2005 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Biological Products (No Diagnostic Substances) | Medical/Dental Instruments |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 5.9M | 5.6M |
| IPO Year | 2015 | 2020 |
| Metric | ALBT | LYRA |
|---|---|---|
| Price | $0.90 | $1.28 |
| Analyst Decision | | Hold |
| Analyst Count | 0 | 1 |
| Target Price | N/A | ★ $16.00 |
| AVG Volume (30 Days) | ★ 8.5M | 71.0K |
| Earning Date | 01-01-0001 | 01-01-0001 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ N/A | N/A |
| Revenue | $1,333,403.00 | ★ $1,534,000.00 |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 6.19 | N/A |
| 52 Week Low | $0.42 | $0.08 |
| 52 Week High | $11.50 | $37.50 |
| Indicator | ALBT | LYRA |
|---|---|---|
| Relative Strength Index (RSI) | 50.71 | 37.54 |
| Support Level | $0.88 | $1.21 |
| Resistance Level | $0.93 | $1.52 |
| Average True Range (ATR) | 0.23 | 0.17 |
| MACD | 0.04 | 0.04 |
| Stochastic Oscillator | 40.76 | 60.90 |
Avalon Globocare Corp is an intelligent biotech developer and healthcare service provider dedicated to promoting and empowering high-impact, transformative biotechnology, clinical applications, and healthcare facility management. The company has two reportable segments: the real property operating segment, which is the key revenue driver, and the laboratory testing services segment. The company focuses on diagnostic and therapeutic areas like early detection of oral cancer, ovarian cancer, kidney cancer, skin regeneration and anti-fibrosis, and treatments of degenerative disorders.
Lyra Therapeutics Inc is a clinical-stage therapeutics company focused on the development and commercialization of novel integrated drug and delivery solutions for the localized treatment of patients. The Company's operations and manages its business as a single operating segment which is the business of developing targeted medicines to address ears, nose, and throat, or ENT diseases. Its initial product candidates, LYR-210 and LYR-220, are bioabsorbable polymeric matrices designed to be administered in a brief, non-invasive, in-office procedure and intended to deliver continuous drug therapy to the sinonasal passages for the treatment of chronic rhinosinusitis, or CRS.